LLY, NFLX, and GE lead todays top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and…
Key PointsAbbott Laboratories is a dividend growth machine thats known for consistency.AbbVies dividend has more than quadrupled since 2013.Eli Lilly…
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.…
…
Key PointsNovo Nordisks beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year.Eli Lillys…
In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading…
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead…
Key PointsThe stocks listed here each increased their dividend payments by more than 10% recently.Although their yields may look unimpressive,…
Key PointsAbbVie offers something for every investor.Eli Lilly could be overdue for a big rally.Vertex Pharmaceuticals is in a new…
…
Key PointsEli Lilly is a leader in the weight loss drug market, generating blockbuster revenue.Viking Therapeutics recently launched a phase…
Key PointsNovo Nordisks shares look attractive after a terrible performance over the past 12 months.DexCom has significant room to grow…
Key PointsInvesting in attractive dividend growth stocks can lead to superior long-term returns.The two healthcare companies below generally deliver excellent…
Key PointsWall Streets smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside…
…
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.…
The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies…
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and…
Stocks are on fire this summer. Driven primarily by artificial intelligence (AI) and its offshoots like advanced robotics, tech stocks…
Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move likely…
…
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.…
…
In this podcast, Motley Fool Chief Investment Officer Andy Cross and contributors Jason Hall and Matt Frankel discuss:
Fair Isaac Corp.…
Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
…
The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.…
The iShares Russell 1000 Growth ETF (NYSEMKT: IWF) is one of the largest and most popular exchange-traded funds (ETFs) focused…
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a…
…
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the…
Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk…
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing…
…
Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large…
It wasnt so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all…
VERV jumps on Eli Lillys buyout offer, adding next-gen gene-editing therapies to the pharma giants pipeline.…
In this video, I will review some of the stock purchases made by members of the U.S. Congress. Politicians such…
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.…
Wall Streets main indexes were on track for a lower open on Tuesday as the Israel-Iran conflict entered its fifth…
…
Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3…
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial…
Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the…
In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the…
Youre unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night…
Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical…
Not many companies that have been around since the late 1800s can claim that theyre growth companies. But Eli Lilly…
Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and…